Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.58 |
| ▸ | MAOA | P21397 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | CES1 | P23141 | 2/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29797486 | 1.00 | MAOB (0.58) | MAOBMAOAALDH1A1CYP3A4HPGD | |
| SCHEMBL31231917 | 0.83 | P2RX1 (0.50) | MAOBMAOAALDH1A1HPGDCES2 | |
| SCHEMBL467241 | 0.83 | P2RX1 (0.50) | MAOBMAOAALDH1A1HPGDCES2 | |
| SCHEMBL16508431 | 0.81 | TTR (0.61) | MAOBMAOAALDH1A1CYP3A4HPGD | |
| SCHEMBL11570 | 0.80 | CES2 (0.68) | MAOBMAOACES2CES1HTT | |
| SCHEMBL188203 | 0.80 | ALDH1A1 (0.61) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL29372550 | 0.80 | CES2 (0.68) | MAOBMAOACES2CES1HTT | |
| SCHEMBL1121927 | 0.78 | CES2 (0.48) | MAOBMAOAALDH1A1CES2CES1 | |
| Hydrochloric Acid SCHEMBL5459426 | 0.78 | ALDH1A1 (0.59) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL1436288 | 0.78 | MAPT (0.50) | MAOBMAOAALDH1A1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 643 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118924749-A | Preparation method of chromone amide compound for Alzheimer disease drug | 广西民族大学 | 2024-11-12 | — | — | CN | claimed |
| CN-116332887-B | Synthesis method and application of orange ketone derivatives with nonalcoholic steatohepatitis resistance | 天津科技大学 | 2024-08-13 | — | — | CN | claimed |
| CN-118146209-A | 7-Sulfur substituent-chromone-3-formaldehyde compound or derivative thereof, and preparation method and application thereof | 中山大学 | 2024-06-07 | — | — | CN | claimed |
| CN-114751870-B | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxybenzoate and derivative thereof, and synthetic method and application thereof | 贵州医科大学 | 2023-10-20 | — | — | CN | claimed |
| CN-116515782-A | Amine dehydrogenase mutant and application thereof in chiral amine alcohol compound synthesis | 中国科学院天津工业生物技术研究所 | 2023-08-01 | — | — | CN | claimed |
| CN-116332887-A | Synthesis method and application of orange ketone derivatives with nonalcoholic steatohepatitis resistance | 天津科技大学 | 2023-06-27 | — | — | CN | claimed |
| CN-114146071-B | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2023-02-28 | — | — | CN | claimed |
| CN-114751870-A | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate and derivative thereof, and synthesis method and application thereof | 贵州医科大学 | 2022-07-15 | — | — | CN | claimed |
| CN-114146071-A | Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome | 西北农林科技大学深圳研究院 | 2022-03-08 | — | — | CN | claimed |
| EP-3253750-B1 | NOVEL FLAVONE BASED EGFR INHIBITORS AND PROCESS FOR PREPARATION THEREOF | COUNCIL SCIENT IND RES (IN) | 2019-04-10 | — | — | EP | claimed |
| US-10221165-B2 | Flavone based EGFR inhibitors and process for preparation thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2019-03-05 | — | — | US | claimed |
| US-20180016268-A1 | Novel Flavone Based EGFR Inhibitors and Process for Preparation Thereof | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-01-18 | — | — | US | claimed |
| WO-2016125186-A1 | NOVEL FLAVONE BASED EGFR INHIBITORS AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-08-11 | — | — | WO | claimed |
| EP-4735449-A1 | TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE | OmniAB, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4719593-A1 | ENANTIOSELECTIVE PREPARATION METHOD | Immunahr AB (SE) | 2026-04-08 | — | — | EP | disclosed |
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2026-04-02 | — | — | US | disclosed |
| US-4578387-A | VASODILATION; DERIVATIVES OF 2-PHENYL-5,6,7,8-TETRAHYDROIMADAZO/1,2-A/PYRAZINE | ELI LILLY AND COMPANY (US) | 1986-03-25 | — | — | US | disclosed |
| EP-0154494-A2 | Phenylimidazole inotropic agents | ELI LILLY AND COMPANY (US) | 1985-09-11 | — | — | EP | disclosed |
| US-4537889-A | PHENYL SUBSTITUTED IMIDAZO COMPOUNDS | ELI LILLY AND COMPANY (US) | 1985-08-27 | — | — | US | disclosed |
| EP-0113236-A1 | Substituted imidazopyrimidines-pyrazines, and -triazines | ELI LILLY AND COMPANY (US) | 1984-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092045-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | TFPI, F3, BTK | MAOB 687/4885MAOA 614/4885ALDH1A1 3179/4885 |
| US-20180016268-A1 | Novel Flavone Based EGFR Inhibitors and Process for Preparation Thereof | EGFR, ERBB2, ABL1 | MAOB 1112/4885MAOA 1733/4885ALDH1A1 1959/4885 |
| US-10221165-B2 | Flavone based EGFR inhibitors and process for preparation thereof | EGFR, ERBB2, ABL1 | MAOB 1202/4885MAOA 1685/4885ALDH1A1 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.